PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33139291-7 2020 Ceftazidime-avibactam was active against 9.1% of carbapenem-resistant E. coli (63.6% were bla NDM-producers) and 84.6% of K. pneumoniae (74.3% were bla KPC-producers) isolates. avibactam 12-21 beta-lactamase Escherichia coli 90-93 30258039-0 2018 Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying bla KPC-2 Reveals a Heterogenous Population and Reversible Genotype. avibactam 26-35 beta-lactamase Escherichia coli 84-87 30258039-1 2018 A bla KPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. avibactam 72-81 beta-lactamase Escherichia coli 2-5 30258039-12 2018 We report a Citrobacter freundii isolate that developed ceftazidime-avibactam resistance due to mutations within the coding region of the bla KPC-2 Omega-loop previously reported; however, in this case, only 11% of the whole-genome sequencing reads had mutations, making this alteration difficult to detect and the treatment of these isolates more challenging. avibactam 68-77 beta-lactamase Escherichia coli 138-141 28039278-1 2017 Objectives: Mycobacterium tuberculosis and Mycobacterium abscessus produce broad-spectrum class A beta-lactamases, BlaC and Bla Mab , which are inhibited by clavulanate and avibactam, respectively. avibactam 173-182 beta-lactamase Escherichia coli 115-118